Laurus Labs is undergoing a significant transformation by shifting its focus towards higher-value segments, with its Contract Development and Manufacturing Organization (CDMO) business now contributing over 30% to total revenue, up from 13% six years ago. This share is projected to reach 50% by FY30, reflecting the company's strategic pivot away from traditional antiretroviral (ARV) therapies.
The CDMO segment experienced a robust 36% year-on-year growth, reaching ₹2,080 crore in FY26. This growth was driven by advancements in the late-stage pipeline, increased commercialization of novel molecules, and strong outsourcing demand from global pharmaceutical companies. Laurus Labs is also diversifying into non-pharma sectors such as crop science and animal health, with expectations from Motilal Oswal Financial Services (MOFSL) that these segments could scale beyond ₹1,000 crore from a current base of about ₹150 crore.
The company's operating margin before depreciation and amortization (Ebitda margin) expanded by 670 basis points year-on-year to 26.8%, attributed to higher operating leverage. While Laurus Labs aims to maintain this margin level, it acknowledges that raw material price volatility could impact trends.
Laurus Labs has planned a capital expenditure of ₹3,000 crore over the next two years, with over 90% allocated to expanding mid and large-scale manufacturing capacities. Key projects include the greenfield Unit 7 facility with over 2,000 cubic meters of reactor capacity and a second commercial block expected to be validated by the September 2026 quarter.
MOFSL has maintained a 'BUY' rating on Laurus Labs' stock, raising earnings estimates for FY27 by 8% and for FY28 by 6% due to stronger CDMO traction and steady growth in ARV and non-ARV segments. The stock closed 0.2% lower at ₹1,450.6 on Thursday on the BSE.
Background
Laurus Labs' strategic shift towards high-value segments and its expansion into non-pharma areas underscore its efforts to reduce reliance on traditional ARV therapies. This move aligns with broader industry trends of diversification and innovation.
Looking ahead, Laurus Labs' continued focus on expanding its CDMO capabilities and entering new markets will be crucial for sustaining growth. Investors and analysts will be watching the company's ability to manage raw material costs and execute its capital expenditure plans effectively.
